Difference between revisions of "Team:Sydney Australia/Patent Law"

Revision as of 10:48, 25 October 2017

GENERAL HEADER ON OUR PATENTS

Although our team attempted to be thorough, we recognise that not all patents can be checked. However, we targeted patents with the greatest relevance to avoid legal suits that may arise. Regardless, our work is for ‘research purposes’ in which an exception exists for patents under WHAT?? Testing of claims from patents are not illegal so long as we do not directly market this product which our team is not pursuing at this stage.

DIMARCHI ET AL.

Single Chain Insulin with high bioactivity

Patent No: US 9458,220 B2

October 4^th 2016

CLAIM

COMPARISON WITH OUR SEQUENCE

Y/N

A single chain insulin agonist analogue with stricture of B-LM-A wherein B represents an insulin B chain comprising the sequence R₂₂X₂₅LCGX₂₉_… and A represents an insulin A chain comprising the sequence

GIVX₄X₅CCX₈_…-R₁₃

Both insulin A and B chains involve R groups which stand for modifications eg. carboxylation. As our insulin B chain does not contain any modifications (except an additional glycine at the A chain), our construct is outside the patent

N

Furthermore the linking moiety linking the carboxy terminus of the B chain to the amino terminus of the A chain; further wherein the linking moiety is an 8 amino acid sequence comprising of the sequence X₅₁X₅₂GSSSX₅₇X₅₈ wherein

X₅₁ = group consisting of glycine, alanine, valine, leucine, isoleucine, isoleucine and ornithine

X₅₂ = any amino acid other than tyrosine

X₅₇ and X₅₈ are independently selected form the ground consisting of arginine, lysine and ornithine

Our amino acid sequence is squarely outside the scope of 8 amino acids.

Even if we did fall within the claim; we do not contain the 8 amino acid sequence using both potential orientations

X₅₁ is glutamine or arginine in our sequence

B-chain – QR . . . RR – A-chain

N

The LM also requires the sequence of GAGSSSRR or a sequence that differs from GAGSSRR by 1 or 2 amino acids

Our sequence is 12 amino acids long and differs by more than 4 amino acids.

N

LM represents linking moiety linking the carboxyl terminus of the B chain to the amino terminus of the a chain, wherein said linking moiety is an 8 amino acid sequence consisting of X₅₁X₅₂X₅₃X₅₄... wherein X₅₁ is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine and proline…

Similarly, the patent claim is over an 8 amino acid sequence. Applying the same principle our;

X₅₁ is glutamine or arginine (depending on orientation) and outside the scope

N

LEE ET AL.

Single Chain Insulin Analog and a polynucleotide sequence encoding the analog

Patent No: US 6,630,348 B1

October 7^th 2003

CLAIM	COMPARISON WITH OUR SEQUENCE	Y/N
A single chain insulin analogue compound of formula (I) having the properties of greater insulin receptor binding activity than proinsulin and less insulin receptor binding activity than insulin: B chain - X – A chain wherein:	General B – X – A chain single chain formula	Y
B and A chain are human insulin chains, respectively and,	Our B and A chain are human insulin chains although our A chain includes a modification (additional glycine)	N
X is a joining peptide of about 5 to 18 amino acids comprising the following sequence: Gly-Gly-Gly-Pro-Gly- Lys-Arg	Where the term ‘comprising’ is included, the patent requires that the specific sequence named MUST be part of the linker region. Although our sequence is 12 amino acids long, it does not contain the ‘GGGPGLR’ identified in the patent	N

LEE ET AL.

Single Chain Insulin Analogs

Patent No: EP 1 193 272 B1

October 30^th 2004

CLAIM

COMPARISON WITH OUR SEQUENCE

Y/N

A single chain insulin analogue compound of formula (I) having the properties of greater insulin receptor binding activity than prosinsulin and less insulin receptor binding activity than insulin:

B Chain – U_I – Z_n – Y – Z_I – U_n– A chain

B and A chain are human insulin chains respectively and

We have a modified A chain

N

U is an arginine or lysine residue

Our ‘U’ is glutamine

N

Z is a glycine

Z Is Glycine

Y

I is an integer of 2 – n

N is an integer of 0 or 2 and

The maximum size of the linker sequence when considering this is 9 amino acids. Since our sequence is 12 amino acids they are outside the scope

N

Y is glycine-proline-glycine, or alanine-proline-glycine-aspartic acid–valine, or tyrosine-proline-glycine-aspartic acid-valine, or histidine-proline-glycine-aspartic acid-valine.

Our sequence has no proline

N

3rd patent shite

INSERT YOUR PATENT HERE

</body> </html>

@@ Line 221: / Line 221: @@
      </div>
      <div class="choose box">
-     <h1> GENERAL HEADER ON OUR PATENTS</h1>
+     <h2> GENERAL HEADER ON OUR PATENTS</h2>
-     <h4>Although our team attempted to be thorough, we recognise that not all patents can be checked. However, we targeted patents with the greatest relevance to avoid legal suits that may arise. Regardless, our work is for ‘research purposes’ in which an exception exists for patents under WHAT?? Testing of claims from patents are not illegal so long as we do not directly market this product which our team is not pursuing at this stage.
+     <h4>Although our team attempted to be thorough, we recognise that not all patents can be checked. However, we targeted patents with the greatest relevance to avoid legal suits that may arise. Regardless, our work is for ‘research purposes’ in which an exception exists for patents under WHAT?? Testing of claims from patents are not illegal so long as we do not directly market this product which our team is not pursuing at this stage. </h4>
-    </h4>
 <p class="MsoNormal" align="center" style="text-align:center"><b style="mso-bidi-font-weight:
 normal"><span lang="EN-AU" style="font-size:20.0pt;font-family:Quicksand">DIMARCHI